Study on data independent acquisition proteomics technology for screening serum protein markers in patients with polycystic ovary syndrome
10.3760/cma.j.cn101441-20240717-00263
- VernacularTitle:数据非依赖采集蛋白组学技术筛选多囊卵巢综合征患者血清蛋白标志物的研究
- Author:
Lifeng TIAN
1
;
Weiqi ZOU
;
Jun TAN
;
Yong LUO
;
Qiongfang WU
;
Faying LIU
Author Information
1. 江西省妇幼保健院辅助生殖医学中心，南昌 330077
- Publication Type:Journal Article
- Keywords:
Polycystic ovary syndrome;
Biomarkers data independent acquisition proteomics;
Peripheral blood;
Biomarker
- From:
Chinese Journal of Reproduction and Contraception
2025;45(4):390-397
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To screen serum biomarkers of polycystic ovary syndrome (PCOS) patients by high throughput data independent acquisition (DIA) proteomics technology.Methods:This was a case-control study. A total of 39 peripheral blood samples were collected at Reproductive Medical Center of Jiangxi Maternal and Child Health Hospital from March to November 2021. Among which, 20 cases were from PCOS patients, and 19 cases were from women who underwent assisted reproduction due to male factors causing infertility. DIA proteomics technology combined with bioinformatics analysis were performed to screen for differential protein expression profiles in the serum of PCOS patients. Typical differentially expressed proteins were selected for expression analysis and receiver operating characteristic (ROC) curve analysis, followed by enzyme-linked immunosorbent assay (ELISA) validation.Results:The results of DIA proteomics combined with bioinformatics analysis showed that compared with control group, 194 significantly differentially expressed proteins were screened in the peripheral blood of PCOS patients, including 64 upregulated proteins and 130 downregulated proteins. The ROC curve analysis results showed that the area under curve values of PSMD8, RPS15A, NDUFB1, GM2A, and TOP2A were all above 0.9, indicating that these proteins have good diagnostic value. The ELISA validation results showed that the content of TOP2A in peripheral blood of PCOS patients was significantly upregulated ( P=0.046), while the content of GM2A was significantly downregulated ( P=0.021), when compared with control group, which consistent with the DIA results. Conclusion:DIA proteomics can be used to screen the differential expression of peripheral blood proteins in PCOS patients, among which, PSMD8, RPS15A, NDUFB1, GM2A and TOP2A can be used as serum biomarkers for PCOS diagnosis and treatment.
